SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktom who wrote (46)6/13/1999 8:29:00 AM
From: tktom  Read Replies (1) of 66
 
Noven's work in the past on insulin....

Dug this up on NOVN's work with insulin...

Drug delivery system, transoral Noven licensing offer, Worldwide
Abstracted from R & D Focus Drug News 06/15/98

Noven's transoral delivery system is available for licensing worldwide. The system is reported to be suitable for delivering bio- or macromolecules and a proof-of-concept study has been conducted in the UK with insulin. Active drug is incorporated into this patch, which can be placed inside the mouths of patients and is expected to confer both improved efficacy and greater patient compliance.
Pauline A Goldsmith, Senior Director, Business Development, Noven Pharmaceuticals, 11960 Southwest 114th Street, Miami, FL 33186, USA; Tel: +1 305 253 5099 ext 101; Fax: +1 305 232 0525; Email: pauline@noven.com.

Drug delivery system, transoral, V7A, All Other Non-Therapeutic Products, Noven, licensing-offer, Worldwide.

(c)Copyright 1994-1999, Responsive Database Services, Inc, All Rights Reserved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext